[1]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30.
https://doi.org/10.3322/caac.21442
|
[2]
|
Chen, W., Zheng, R., Zeng, H., Zhang, S. and He, J. (2015) Annual Report on Status of Cancer in China, 2011. Chinese Journal of Cancer Research, 27, 2-12.
|
[3]
|
Babjuk, M., Bohle, A., Burger, M., Capoun, O., Cohen,
D., Compérat, E.M., et al. (2017) EAU Guidelines on
Non- Muscle-Invasive Urothelial Carcinoma of the
Bladder: Update 2016. European Urology, 71, 447-461.
https://doi.org/10.1016/j.eururo.2016.05.041
|
[4]
|
Sylvester, R.J., van der Meijden, A.P., Oosterlinck,
W., Alfred Witjes, J., Bouffioux, C., Denis, L., et al. (2006) Predicting Recurrence and Progression in
Individual Patients with Stage Ta T1 Bladder Cancer
Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. European Urology,
49, 466-477.
https://doi.org/10.1016/j.eururo.2005.12.031
|
[5]
|
Fernandez-Gomez, J., Madero, R., Solsona, E., Unda,
M., Martinez-Piñeiro, L., Ojea, A., et al. (2011)
The EORTC Tables Overestimate the Risk of Recurrence
and Progression in Patients with Non-Muscle-Invasive
Bladder Cancer Treated with Bacillus Calmette-Guerin: External Validation of the EORTC Risk Tables.
European Urology, 60, 423-430.
https://doi.org/10.1016/j.eururo.2011.05.033
|
[6]
|
Kang, M., Jeong, C.W., Kwak, C., Kim, H.H. and Ku, J.H. (2016) Single, Immediate Postoperative Instillation of Chemotherapy in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials Using Different Drugs. Oncotarget, 7, 45479-45488. https://doi.org/10.18632/oncotarget.9991
|
[7]
|
Cambier, S., Sylvester, R.J., Collette, L., Gontero, P., Brausi, M.A., van Andel, G., et al. (2016) EORTC
Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival
in Non-Muscle- Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette- Guerin. European Urology, 69, 60-69. https://doi.org/10.1016/j.eururo.2015.06.045
|
[8]
|
Herr, H.W. and Dalbagni, G. (2003) Defining Bacillus Calmette-Guerin Refractory Superficial Bladder Tumors. Journal of Urology, 169, 1706-1708. https://doi.org/10.1097/01.ju.0000062605.92268.c6
|
[9]
|
Kassouf, W., Traboulsi, S.L., Kulkarni, G.S., Breau, R.H., Zlotta, A., Fairey, A., et al. (2015) CUA Guidelines on the Management of Non-Muscle Invasive Bladder Cancer. Canadian Urological Association Journal, 9, E690-E704.
|
[10]
|
Chang, S.S., Boorjian, S.A., Chou, R., Clark, P.E., Daneshmand, S., Konety, B.R., et al. (2016) Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. Journal of Urology, 196, 1021-1029.
https://doi.org/10.1016/j.juro.2016.06.049
|
[11]
|
Kamat, A.M., Colombel, M., Sundi, D., Lamm, D., Boehle, A., Brausi, M., et al. (2017) BCG-Unresponsive Non- Muscle-Invasive Bladder Cancer: Recommendations from the IBCG. Nature Reviews Urology, 14, 244-255.
https://doi.org/10.1038/nrurol.2017.16
|
[12]
|
靳英辉, 曾宪涛. 中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南(2018简化版) [J]. 中国循证医学杂志, 2018, 18(12): 1267-1272.
|
[13]
|
Nieder, A.M, Brausi, M., Lamm, D., O’Donnell, M., Tomita, K., Woo, H., et al. (2005) Management of Stage T1 Tumors of the Bladder: International Consensus Panel. Urology, 66, 108-125.
https://doi.org/10.1016/j.urology.2005.08.066
|
[14]
|
Kamat, A.M., Sylvester, R.J., Bohle, A., Palou, J., Lamm, D.L., Brausi, M., et al. (2016) Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Journal of Clinical Oncology, 34, 1935-1944. https://doi.org/10.1200/jco.2015.64.4070
|
[15]
|
U.S. Department of Health and Human Services, Food
and Drug Administration, Center for Drug Evaluation
and Research (CDER) and Center for Biologics Evaluation
and Research (CBER) (2018) BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics
for Treatment Guidance for Industry. Food and Drug Administration, Rockville.
https://www.fda.gov/downloads/Drugs/Guidance
ComplianceRegulatoryInformation/Guidances/UCM529600.pdf
|
[16]
|
Jung, A., Nielsen, M.E., Crandell, J.L., Palmer, M.H., Bryant, A.L., Smith, S.K., et al. (2018) Quality of Life in Non- Muscle-Invasive Bladder Cancer Survivors: A Systematic Review. Cancer Nursing, 42, E21-E33.
https://doi.org/10.1097/ncc.0000000000000606
|
[17]
|
Bui, T.T. and Schellhammer, P.F. (1997) Additional Bacillus Calmette-Guerin Therapy for Recurrent Transitional Cell Carcinoma after an Initial Complete Response. Urology, 49, 687-691. https://doi.org/10.1016/S0090-4295(97)00067-8
|
[18]
|
Dalbagni, G. and Herr, H.W. (2000) Current Use and Questions Concerning Intravesical Bladder Cancer Group for Superficial Bladder Cancer. Urologic Clinics of North America, 27, 137-146.
https://doi.org/10.1016/S0094-0143(05)70241-X
|
[19]
|
Catalona, W.J., Hudson, M.A., Gillen, D.P., Andriole, G.L. and Ratliff, T.L. (1987) Risks and Benefits of Repeated Courses of Intravesical Bacillus Calmette-Guerin Therapy for Superficial Bladder Cancer. Journal of Urology, 137, 220-224. https://doi.org/10.1016/S0022-5347(17)43959-0
|
[20]
|
Dinney, C.P., Greenberg, R.E. and Steinberg, G.D. (2013) Intravesical Valrubicin in Patients with Bladder Carcinoma in Situ and Contraindication to or Failure after Bacillus Calmette-Guerin. Urologic Oncology, 31, 1635-1642.
https://doi.org/10.1016/j.urolonc.2012.04.010
|
[21]
|
Dalbagni, G., Russo, P., Sheinfeld, J., Mazumdar, M., Tong, W., Rabbani, F., et al. (2002) Phase I Trial of Intravesical Gemcitabine in Bacillus Calmette-Guerin-Refractory Transitional-Cell Carcinoma of the Bladder. Journal of Clinical Oncology, 20, 3193-3198. https://doi.org/10.1200/jco.2002.02.066
|
[22]
|
Skinner, E.C., Goldman, B., Sakr, W.A., Petrylak, D.P., Lenz, H.J., Lee, C.T., et al. (2013) SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Guerin. Journal of Urology, 190, 1200-1204.
https://doi.org/10.1016/j.juro.2013.04.031
|
[23]
|
McKiernan, J.M., Masson, P., Murphy, A.M., Goetzl, M., Olsson, C.A., Petrylak, D.P., et al. (2006) Phase I Trial of Intravesical Docetaxel in the Management of Superficial Bladder Cancer Refractory to Standard Intravesical Therapy. Journal of Clinical Oncology, 24, 3075-3080. https://doi.org/10.1200/jco.2005.03.1161
|
[24]
|
Milbar, N., Kates, M., Chappidi, M.R., Pederzoli, F., Yoshida, T., Sankin, A., et al. (2017) Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 3, 293-303. https://doi.org/10.3233/BLC-170126
|
[25]
|
Barlow, L.J., McKiernan, J.M. and Benson, M.C. (2013) Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer after Previous Bacillus Calmette-Guerin Therapy. Journal of Urology, 189, 834-839. https://doi.org/10.1016/j.juro.2012.10.068
|
[26]
|
Racioppi, M., Di Gianfrancesco, L., Ragonese, M., Palermo, G., Sacco, E. and Bassi, P.F. (2018) ElectroMotive Drug Administration (EMDA) of Mitomycin C as First-Line Salvage Therapy in High Risk “BCG Failure” Non Muscle Invasive Bladder Cancer: 3 Years Follow-up Outcomes. BMC Cancer, 18, Article No. 1224.
https://doi.org/10.1186/s12885-018-5134-7
|
[27]
|
Soria, F., Milla, P., Fiorito, C., Pisano, F., Sogni, F., Di Marco, M., et al. (2016) Efficacy and Safety of a New Device for Intravesical Thermochemotherapy in Non-Grade 3 BCG Recurrent NMIBC: A Phase I-II Study. World Journal of Urology, 34, 189-195. https://doi.org/10.1007/s00345-015-1595-3
|
[28]
|
Dinney, C.P., Fisher, M.B., Navai, N., O’Donnell, M.A., Cutler, D., Abraham, A., et al. (2013) Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-Alpha2b Formulated in Syn3 for Bacillus Calmette-Guerin Failures in Nonmuscle Invasive Bladder Cancer. Journal of Urology, 190, 850-856.
https://doi.org/10.1016/j.juro.2013.03.030
|
[29]
|
Shore, N.D., Boorjian, S.A., Canter, D.J., Ogan, K., Karsh, L.I., Downs, T.M., et al. (2017) Intravesical rAd-IFNalpha/ Syn3 for Patients with High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. Journal of Clinical Oncology, 35, 3410-3416.
https://doi.org/10.1200/jco.2017.72.3064
|
[30]
|
Nykopp, T.K., Batista da Costa, J., Mannas, M. and Black, P.C. (2018) Current Clinical Trials in Non-Muscle Invasive Bladder Cancer. Current Urology Reports, 19, Article No. 101. https://doi.org/10.1007/s11934-018-0852-6
|
[31]
|
Burke, J.M., Lamm, D.L., Meng, M.V., Nemunaitis, J.J., Stephenson, J.J., Arseneau, J.C., et al. (2012) A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer. Journal of Urology, 188, 2391-2397. https://doi.org/10.1016/j.juro.2012.07.097
|
[32]
|
Sidi, A.A., Ohana, P., Benjamin, S., Shalev, M., Ransom, J.H. and Lamm, D., et al. (2008) Phase I/II Marker Lesion Study of Intravesical BC-819 DNA Plasmid in H19 Over Expressing Superficial Bladder Cancer Refractory to Bacillus Calmette-Guerin. Journal of Urology, 180, 2379-2383. https://doi.org/10.1016/j.juro.2008.08.006
|
[33]
|
Biot, C., Rentsch, C.A., Gsponer, J.R., Birkhäuser, F.D., Jusforgues-Saklani, H., Lemaître, F., et al. (2012) Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer. Science Translational Medicine, 4, 137ra172. https://doi.org/10.1126/scitranslmed.3003586
|
[34]
|
Gourd, E. (2018) Neoadjuvant Pembrolizumab in Bladder Cancer. Lancet Oncology, 19, Article No. e669.
https://doi.org/10.1016/S1470-2045(18)30814-3
|
[35]
|
Fishman, M.N., Thompson, J.A., Pennock, G.K., Gonzalez, R., Diez, L.M., Daud, A.I., et al. (2011) Phase I trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264-272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies. Clinical Cancer Research, 17, 7765-7775.
https://doi.org/10.1158/1078-0432.ccr-11-1817
|
[36]
|
Wrangle, J.M., Velcheti, V., Patel, M.R., Garrett-Mayer, E., Hill, E.G., Ravenel, J.G., et al. (2018) ALT-803, an IL-15 Superagonist, in Combination with Nivolumab in Patients with Metastatic Non-Small Cell Lung Cancer: A Non-Rando- mised, Open-Label, Phase 1b Trial. Lancet Oncology, 19, 694-704. https://doi.org/10.1016/S1470-2045(18)30148-7
|
[37]
|
Jinesh, G.G., Lee, E.K., Tran, J. and Kamat, A.M. (2013) Lenalidomide Augments the Efficacy of Bacillus Calmette- Guerin (BCG) Immunotherapy in Vivo. Urologic Oncology, 31, 1676-1682.
https://doi.org/10.1016/j.urolonc.2012.05.007
|
[38]
|
Wittlinger, M., Rodel, C.M., Weiss, C., Krause, S.F., Kühn, R., Fietkau, R., et al. (2009) Quadrimodal Treatment of High-Risk T1 and T2 Bladder Cancer: Transurethral Tumor Resection Followed by Concurrent Radiochemotherapy and Regional Deep Hyperthermia. Radiotherapy and Oncology, 93, 358-363.
https://doi.org/10.1016/j.radonc.2009.09.018
|